Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
883 3 |
Ultima descărcare din IBN: 2021-04-03 17:51 |
SM ISO690:2012 PELTEC, Angela. Hemoglobin level as a cardiovascular risk factor
in nafld. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2013, nr. 1(37), pp. 123-126. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 1(37) / 2013 / ISSN 1857-0011 | ||||||
|
||||||
Pag. 123-126 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease. Identification of novel risk factors for NAFLD has practical implications for the selection of cases for histologic assessment of disease severity and progression in the presence of abnormal liver enzymes, as well as the opening of new treatment avenues. Hemoglobin concentrations were the chief predictor of both NASH and severe fibrosis in NAFLD, but in other contest could affect the cardiovascular system through oxygen supply and blood viscosity. The relation Hemoglobine - NAFLD – Cardiovascular Disease may open a new perspective in management of NAFLD and could lead to the development of novel therapeutic avenues in treatment of this chronic liver disorder. |
||||||
Cuvinte-cheie nonalcoholic fatty liver disease, hemoglobin level, cardiovascular disease |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-29184</cfResPublId> <cfResPublDate>2013-01-02</cfResPublDate> <cfVol>37</cfVol> <cfIssue>1</cfIssue> <cfStartPage>123</cfStartPage> <cfISSN>1857-0011</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/29184</cfURI> <cfTitle cfLangCode='EN' cfTrans='o'>Hemoglobin level as a cardiovascular risk factor in nafld</cfTitle> <cfKeyw cfLangCode='EN' cfTrans='o'>nonalcoholic fatty liver disease; hemoglobin level; cardiovascular disease</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'>Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease. Identification of novel risk factors for NAFLD has practical implications for the selection of cases for histologic assessment of disease severity and progression in the presence of abnormal liver enzymes, as well as the opening of new treatment avenues. Hemoglobin concentrations were the chief predictor of both NASH and severe fibrosis in NAFLD, but in other contest could affect the cardiovascular system through oxygen supply and blood viscosity. The relation Hemoglobine - NAFLD – Cardiovascular Disease may open a new perspective in management of NAFLD and could lead to the development of novel therapeutic avenues in treatment of this chronic liver disorder.</cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'>Boala fi catului gras nealcoolic (BFGNA) este în prezent cea mai comună formă a bolii hepatice cronice. Identifi carea factorilor de risc pentru BFGNA are implicaţii practice pentru selectarea cazurilor pentru evaluarea histologică de severitate a bolii şi progresie în prezenţa sindromului de citoliză, precum şi deschiderea unor căi noi de tratament. Concentraţia hemoglobinei a fost predictor principal atât a steatohepatitei, cât şi fi brozei severe în BFGNA, dar în alt context ar putea afecta sistemul cardiovascular, prin asigurarea cu oxigen şi vâscozitatea sanguină. Relaţia Hemoglobina - BFGNA – Patologia Cardiovasculară poate deschide o nouă perspectivă în managementul BFGNA şi ar putea direcţiona dezvoltarea unor căi noi terapeutice în tratamentul acestei afecţiuni hepatice cronice.</cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'>Безалкогольная жирoвая болезнь печени (БАЖБП) в настоящее время является наиболее распространенной формой хронического заболевания печени. Выявление новых факторов риска БАЖБП имеет практическое значение для отбора пациентов для биопсии печени для оценки тяжести заболевания в присутствии цитолитического синдрома, а также открытие новых путей лечения. Гемоглобина были главным предиктором как стеатогепатита, так и тяжелого фиброза при БАЖБП, с другой стороны он может повлиять на развитие сердечно-сосудистой патологии посредством обеспечения кислородом и определяя вязкость крови. Взаимоотношения Гемоглобин - БАЖБП - Сердечно-сосудистые заболевания может открыть новые перспективы в управлении БАЖБП и может привести к развитию новых терапевтических направлений в лечении этого хронического заболевания печени.</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2013-01-02T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2013-01-02T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11473</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2013-01-02T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11473</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11473-3</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2013-01-02T24:00:00</cfStartDate> <cfFamilyNames>Peltec</cfFamilyNames> <cfFirstNames>Angela</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>